Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8J9SF)

Drug Name
SCH-C Drug Info
Synonyms
Ancriviroc; SCH-C & AOP-RANTES; SCH 351125 & SCH 351125 (non-stereospecific); SCH 351125; CHEMBL78535; 305792-46-5; Methanone, (4-bromophenyl)(1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl(1,4'-bipiperidin)-4-yl)-, O-ethyloxime, (Z)-, N1-oxide & Methanone, (4-bromophenyl)(1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl(1,4'-pipiperidin)-4-yl)-, O-ethyloxime, N1-oxide; 1'-[(2,4-Dimethyl-1-oxidopyridin-3-yl)carbonyl]-4'-methyl-1,4'-bipiperidine; Methanone,; Ancriviroc; SCH C; SCH351125; SC-351125; SCH 351125 AOP-RANTES; SCH-351125; SCH-C cpd; AK671/SCH-C; SCH 351125 & AOP-RANTES; SCH-C & PA14; SCH-C AOP-RANTES; SCH-C & AOP-RANTES; Methanone, (4-bromophenyl)[1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl[1,4'-bipiperidin]-4-yl]-, O-ethyloxime, (Z)-, N1-oxide; Methanone, (4-bromophenyl)[1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl[1,4'-bipiperidin]-4-yl]-, O-ethyloxime, (Z)-, N1-oxide & AOP-RANTES; Methanone, (4-bromophenyl)[1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl[1,4'-bipiperidin]-4-yl]-, O-ethyloxime, (Z)-, N1-oxide & PRO 140 (Anti-CCR5 monoclonal antibody); Methanone, (4-bromophenyl)(1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl(1,4'-bipiperidin)-4-yl)-, O-ethyloxime, (Z)-, N1-oxide AOP-RANTES; Methanone, (4-bromophenyl)(1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl(1,4'-bipiperidin)-4-yl)-, O-ethyloxime, (Z)-, N1-oxide & AOP-RANTES; (2,4-Dimethyl-1-oxy-pyridin-3-yl)-(4'-methyl-[1,4']bipiperidinyl-1'-yl)-methanone; 4-((4-bromophenyl)-(ethoxyimino)methyl)-1'-((2,4-dimethyl-3-pyridinyl)carbonyl)-4'-methyl-1,4'-bipiperidine N-oxide; [3H]ancriviroc
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
9574343
ChEBI ID
CHEMBL78535
CAS Number
CAS 305792-46-5
TTD Drug ID
DM8J9SF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting C-C chemokine receptor type 5 (CCR5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Maraviroc DMTL94F Human immunodeficiency virus infection 1C62 Approved [4]
Vicriviroc DMMTW9K Human immunodeficiency virus infection 1C62 Phase 3 [5]
PRO-140 DMD1FTP Human immunodeficiency virus infection 1C62 Phase 3 [6]
E-913 DMUHS5Q Human immunodeficiency virus infection 1C62 Phase 3 [7]
PRO 140 DMCGK6X Human immunodeficiency virus-1 infection 1C62 Phase 2/3 [8]
INCB9471 DMMWC6F Infectious disease 1A00-CA43.1 Phase 2a [7]
Cenicriviroc DM4V8WF Human immunodeficiency virus infection 1C62 Phase 2 [9]
BMS-813160 DMKY638 Diabetic nephropathy GB61.Z Phase 2 [10]
SB-728-T DMRWE5D Human immunodeficiency virus infection 1C62 Phase 2 [11]
PF-232798 DM8T6KQ Human immunodeficiency virus infection 1C62 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting CCR5 messenger RNA (CCR5 mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Maraviroc DMTL94F Human immunodeficiency virus infection 1C62 Approved [13]
DdRNAi therapy rHIV7-shl-TAR-CCR5RZ, stem cells DM0I5LM Human immunodeficiency virus infection 1C62 Phase 1/2 [14]
viral macrophage inflammatory protein-II DMAXOPS Discovery agent N.A. Investigative [15]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-C chemokine receptor type 5 (CCR5) TT2CEJG CCR5_HUMAN Binder [2]
CCR5 messenger RNA (CCR5 mRNA) TTJIH8Q CCR5_HUMAN Antagonist [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 804).
2 Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94.
3 Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005 Dec;49(12):4911-9.
4 Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. Antiviral Res. 2009 Jul;83(1):86-9.
5 HIV entry: new insights and implications for patient management. Curr Opin Infect Dis. 2009 Feb;22(1):35-42.
6 Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication. J Pharmacol Exp Ther. 2011 Jun;337(3):655-62.
7 Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol. 2007 Dec 5;7(12):1528-34.
8 The return of PRO 140, a CCR5-directed mAb. Curr Opin HIV AIDS. 2018 Jul;13(4):346-353.
9 The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. J Antimicrob Chemother. 2015 Mar;70(3):750-6.
10 A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
11 Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV. N Engl J Med. 2014 March 6; 370(10): 901-910.
12 An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). J Med Chem. 2011 Jan 13;54(1):67-77.
13 Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol. 2005 Dec 19;71(1-2):163-72.
14 Progress on RNAi-based molecular medicines. Int J Nanomedicine. 2012; 7: 3971-3980.
15 A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997 Sep 12;277(5332):1656-9.